Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Farkasgyepu – page 11

162 clinical trials in Farkasgyepu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Farkasgyepu at a glance
162
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

162 trials in Farkasgyepu

Open in trial search

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Qilu Pharmaceutical Co. Ltd.

Rheumatoid arthritis

Not recruiting

Study of lutikizumab and ravagalimab in adults with moderate to severe rheumatoid arthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Obesity+1

Not recruiting

Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Type 2 diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim Espana S.A.

Pain+1

Not recruiting

Comparison of bovine and marine chondroitin sulfate tablets (800 mg) in treating knee osteoarthritis pain and functional impairment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Chondroitin sulfate (marine)
  • Sponsor:IBSA Institut Biochimique SA

Obesity+1

Not recruiting

Study on the Effects of PF-07976016 and Liraglutide in Adults with Obesity

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Liraglutide
  • Sponsor:Pfizer Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Cough

Not recruiting

Study on the Effects of Camlipixant in Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Camlipixant
  • Sponsor:Bellus Health Inc.

Atrial fibrillation

Not recruiting

Study on the Safety and Tolerability of Abelacimab Compared to Rivaroxaban in Patients with Atrial Fibrillation

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Study on Benralizumab and Mometasone Furoate for Patients with Severe Eosinophilic Chronic Rhinosinusitis with Nasal Polyps and Asthma

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Astrazeneca AB

Hypertension

Not recruiting

Study on Baxdrostat for Reducing Blood Pressure in Patients with Uncontrolled or Resistant Hypertension

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:Astrazeneca AB

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Farkasgyepu

What the registry says about research in the country

01 Lung Cancer Immunotherapy

Innovative clinical trials exploring immunotherapy combinations for advanced non-small cell lung cancer (NSCLC), focusing on treatment options for patients with various stages of the disease.

  • Novel immunotherapy combinations
  • PD-L1 targeted therapies
  • First-line treatment strategies

Research aims to improve survival rates and treatment outcomes through targeted immunological approaches.

02 Advanced NSCLC Treatments

Studies evaluating targeted therapies for specific mutations in non-small cell lung cancer, including HER2 and KRAS G12C mutations.

  • Mutation-specific treatments
  • Combination therapy approaches
  • Novel drug development

Investigations focus on personalized treatment strategies for different NSCLC subtypes.

03 Small Cell Lung Cancer Research

Clinical trials examining new therapeutic options for small cell lung cancer, including novel drug combinations and comparative effectiveness studies.

  • Single-agent therapies
  • Combination treatments
  • Survival outcome studies

Research focuses on improving treatment options for patients with relapsed SCLC.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.